← board
BIAF
distress 6/10 · elevated risk$0.71+0%today-94% from 52w high
Lead: lung cancer · est. market ~$35B (approx, global)
Revenue
pre-revenue
Liquidity
$3M
Runway
0.3 yrs
Shares 1y
-84%
Price & events
-47.8% over 6M
CatalystRating changeDilutionFinancingdashed = today
+0.3%
1D
-0.3%
1W
-15.8%
1M
-69.1%
3M
-47.4%
6M
-93.2%
1Y
-99.1%
2Y
—
5Y
-99.7%
All
Overview
- Market Cap
- $3.22M
- Volume
- 14.05K
- 52 Week Range
- $0.70 – $10.95
- Total Shares
- 4.53M
- Float Shares
- 4.42M
- Short %
- 13.18%
- % Held by Insiders
- 2.29%
- % Held by Institutions
- 6.44%
- RVOL
- 0.03x
- Beta
- -1.11
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 4
- July 21, 2026 at 6:00 pm ETConfirmed 100%conferencedata presentationsecondaryCyPath Lung · Webinar on veteran lung health screening collaboration with Philips and 4DMedical.SEC 8-K
- 2026-06-16partnershipCyPath Lung · Collaboration with Philips to enhance lung cancer screening for U.S. veterans.SEC 8-K
- Tuesday, June 16, 2026 at 7 p.m. ETconferencedata presentationsecondaryCyPath Lung · Multidisciplinary panel to discuss CyPath Lung in detection and management of early-stage lung cancer.SEC 8-K
- December 8, 2025conferencedata presentationsecondaryCyPath® Lung · Poster presentation at American Cancer Society National Lung Cancer RoundtableSEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
Shares out: 4,534,906 · 0 offerings/1y · 0 PIPEs
- none
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- 2025-04-01Maxim GroupBuy → Hold
- 2024-07-23Maxim GroupBuy
Competitors — lung cancer
Recent news
- 2026-07-22BioAffinity Technologies Inc (BIAF) Fundamental & Financial Data - Stocktwits
- 2026-07-22bioAffinity Technologies and Pictor Partner to Develop High-Throughput, Cost-Effective Diagnostics for Asthma and COPD – Minichart - Minichart
- 2026-07-22bioAffinity partners with Pictor on asthma, COPD tests - Investing.com
- 2026-07-22bioAffinity Technologies partners with Pictor to develop high-throughput asthma and COPD diagnostics - TradingView
- 2026-07-22, Inc. Partner to Develop and Commercialize bioAffinity’s Diagnostics for Asthma and COPD - Business Wire
- 2026-07-19Certain Common Stock of bioAffinity Technologies, Inc. are subject to a Lock-Up Agreement Ending on 19-JUL-2026. - marketscreener.com
- 2026-07-15bioAffinity Technologies Initiates New Study for Expanding CyPath Lung Tech - Medical Product Outsourcing
- 2026-07-09BIAF Stock Plunges 77% in 3 Months: Should You Still Hold or Sell? - Yahoo Finance
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.